In Spite of Negative Indirect Attempts to Downgrade Portola, It Remains One of Our Favorites

On Nov. 21, 2017, Portola Pharmaceuticals (PTLA) announced that the U.S. Food and Drug Administration (FDA) has informed it that it will respond to the Prior Approval Supplement (PAS) request to change the current manufacturing release specification within the standard 60-day extension period.

No additional information was requested at this time. The new action date is January 30, 2018.

Bill Lis, chief executive officer of Portola said, “As we communicated earlier this month, we’ve made good progress with the FDA and have established an agreement in principle on the change to our product . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.